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1 Introduction
Since its widespread clinical introduction in the late 
1980s, prostate-specific antigen (PSA) testing has gained 
popularity and has revolutionized the diagnosis of pros-
tate cancer [1].  PSA is a kallicrein-like serine protease 
(33 kDa) produced almost exclusively by the epithelial 
cells of the prostate.  Prostate cancer is commonly as-
sociated with serum PSA levels that are higher than 
those observed in benign prostatic hyperplasia (BPH), 
and thus has been widely used to screen the malignant 
condition from the benign one.  In fact, PSA level as 
an independent variable is a better predictor of cancer 
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than a suspicious finding on digital rectal examination 
or trans-rectal ultrasound [2].  As a result, the number of 
locally advanced or metastatic cases of prostate cancer 
has progressively decreased.  However, for practical and 
clinical purposes, PSA is organ- but not cancer-specific 
to the prostate gland.  A limitation of PSA as a tumor 
marker is the substantial overlap in values between men 
with benign alterations (prostatic hyperplasia, prostati-
tis, urinary retention) and those with prostate cancer [1]. 
Furthermore, the PSA threshold that warrants additional 
evaluation is still a matter of discussion; there is no cur-
rently accepted lower cutoff value, although a value of 
4.0 ng mL-1 has been used in many studies.  In addition, 
the prostate biopsy strategy may change according to 
the PSA values, and such an approach can be planned 
individually [3].  In younger men (50–66 years old), the 
cancer detection rate has been found to be as high as 
13.2% in the PSA interval 3–4 ng mL-1 [4].  In a recent 
study of 12 078 men aged under 50 years, a cutoff value 
of 2.0–2.5 ng mL-1 was deemed to be the one most rea-
sonable in contemporary practice [5].
As the PSA value lacks sensitivity and specificity 
for detection of prostate cancer, alternative PSA deriva-
tives have been evaluated for potential use in testing: 
free/total PSA (f/t PSA) [6] and PSA velocity (PSAV). 
PSAV has been identified as a potential clinical marker 
for this purpose.  A PSAV of 0.75 ng mL-1 per year, or 
an annual increase of 20%, is suggestive of prostate 
cancer [7–11], and this level is accepted as a valid pa-
rameter for indicating prostate biopsy.  Moreover, PSAV 
is associated with some characteristics of tumor aggres-
siveness, such as Gleason score [12], and a PSA increase 
of  > 2.0 ng mL-1 in the year before diagnosis has been 
found to be associated with a higher risk of death due to 
prostate cancer after radical prostatectomy or radiation 
therapy [13, 14].  A more recent study suggested that 
the cutoff for distinguishing the most aggressive forms 
of prostate cancer could be set at 0.35 ng mL-1 per year 
[15].
However, it is necessary to distinguish the increases 
in PSA caused by the presence of cancer tissue from the 
physiological fluctuations of PSA.  Several studies have 
investigated PSAV in the cancer population compared 
with PSAV in the non-cancer population; however, 
an adequate analysis of longitudinal fluctuation in the 
normal population has been lacking.  In addition, the 
majority of studies investigating a PSAV threshold have 
been done in a selected population, usually composed 
of relatively young men, and have thus failed to detect 
the underlying physiological fluctuation that may occur 
in middle-aged or elderly men.
The aim of our study was to retrospectively as-
sess PSA variations in elderly men who had PSA 
values < 2.0 ng mL-1 for a 5- to 10-year period in an at-
tempt to define physiological fluctuation.  The research 
focuses on PSA kinetics, and the results will contribute 
to defining the threshold of PSAV as a diagnostic tool 
for prostate cancer.  
2  Materials and methods
Beginning in March 2006, we analyzed retrospec-
tive PSA data from the Central Laboratory of the Hospi-
tal-University of Modena (Modena, Italy), in search of a 
specific cohort of male patients aged > 75 years in 2005 
and with PSA values < 2.0 ng mL-1.  For each subject, 
a retrospective search for PSA values recorded over the 
previous 10 years was made for the purpose of creating 
a database of patients meeting the following criteria: (1) 
a minimum of five PSA measurements, (2) over at least 
5 years.  The exclusion criteria were: (1) a PSA level 
< 0.2 ng mL-1 at every test and (2) having had more than 
one PSA test each year.  These criteria were intended to 
reduce the risk of including subjects with clinical prosta-
tis or of a diagnosis or recurrence of prostate cancer.
Annual PSA measurements were assessed longitu-
dinally and collected in a database.  The variation from 
the first to the last PSA measurement was calculated for 
each patient, as well as the variation from the lowest to 
the highest PSA value throughout the course of follow-
up, to assess the major sources of individual variation. 
These two variables were divided by the number of 
years of follow-up to obtain the mean annual variation 
in PSA from the first to the last and from the lowest to 
the highest measurement for each patient.  
All data were entered in a statistical database 
(Statistical Package for Social Sciences for Windows, 
version 13; SPSS, Chicago, IL, USA).  Descriptive 
analyses of all variables were recorded, and statistical 
analyses were performed using the paired samples t-test 
and the Mann-Whitney U test.  The cutoff for statistical 
significance (P) was fixed at 0.05.
3  Results
Throughout 2005, data from 20 000 patients aged 
> 75 years and with a PSA < 2.0 ng mL-1 were col-
lected.  In total, 1 327 subjects fit the inclusion criteria 
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(more than five PSA measurements for at least 5 years) 
and were eligible for the study.  
The mean age in 2005 was 78.52 ± 3.35 years (range: 
75–89 years).  The mean variation from the first to the 
last PSA measurement was 0.05 ± 0.43 (range: –1.46 to 
1.49) (variable A) for a mean follow-up of 6.79 ± 1.71 
years.  During the same period, the mean fluctuation 
from the lowest to the highest PSA value was 0.04 ± 0.55 
(variable B).  No statistically significant difference was 
found (P = 0.925) between variables A and B.
Additionally, the mean annual fluctuation (variable 
C) was calculated by dividing variable A by the number 
of years of observation for each patient, and the mean 
variation per year was set at 0.0104 ± 0.1050 (range: 
–0.5 to 0.6).  Similarly, we divided the maximal indi-
vidual fluctuation (variable B) by the number of years, 
obtaining a mean of 0.0123 ± 0.1260 (range: –0.5 to 0.6) 
(variable D).  The comparison between variables C and 
D was not significant (P = 0.25).
Figure 1 shows the mean annual fluctuation (variable 
C) stratified for PSA range (< 1 ng mL-1 and 1–2 ng mL-1 
in the first PSA measurement).
Of the 1 327 subjects, we studied a subgroup of 71 
individuals with 7 years of consecutive PSA assessment. 
The fluctuation across years of observation was not sig-
nificant (P = 0.137 between the 1st and 2nd years, P = 
0.162 between the 2nd and 3rd years, P =  0.166 between 
the 3rd and 4th years, P = 0.67 between the 4th and 5th 
years, P = 0.88 between the 5th and 6th years and P = 
0.694 between the 6th and 7th years [Figure 2]).  For 
these 71 individuals, we calculated the mean PSA values 
from the first to the last measurement, fluctuation from 
the lowest to the  highest measurement and PSAV; the re-
sults of these calculations were 0.06 ± 0.52 ng mL-1 (range: 
–1.22 to 1.55 ng mL-1), 0.02 ± 0.80 ng mL-1 (range: –1.9 
to 1.8 ng mL-1) and 0.01 ± 0.07 ng mL-1 per year (range: 
–0.15 to 0.26 ng mL-1), respectively.
4  Discussion
PSA assessment has been widely performed be-
cause of its usefulness in the diagnosis of early pros-
tate cancer, with the measurement of PSAV improving 
the detection of such neoplasm.  In the previous study 
focusing on PSA kinetics, Carter et al. [7] found that 
PSA level as a function of time in patients with local-
ized prostate cancer was significantly higher than that 
in men without prostate cancer 5 years before diagno-
sis.  Several authors have concluded that the increase in 
PSA values in patients with prostate cancer is 10-fold 
greater than in the case of BPH (0.3 ng mL-1) [7, 15, 
16].  However, there are physiological and biological 
fluctuations in PSA level that can occur even in non-
cancer conditions.  For example, Tchetgen et al. [17] 
reported a statistically significant increase in PSA levels 
after ejaculation in 87% of men older than 50 years. 
Rapid increases in PSA values were described even 
after digital rectal examination or cystoscopy [1], and, 
as published recently, sexually transmissible infections 
can induce a 40% increase in PSA [18].  Beyond the 
fluctuation owing to ejaculation, sexual function or 
medical problems, Roehrborn et al. [19] reported that in 
Figure 1.  Mean annual fluctuation (variable C) stratified for 
prostate-specific antigen (PSA) range (< 1 ng mL-1 and 1–2 ng mL-1 
in the first PSA measurement) .
Figure 2.  Mean prostate-specific antigen (PSA) values per year 
in a subgroup of 71 patients with 7 years of consecutive PSA 
assessment (P = 0.137 between the 1st and 2nd years; P = 0.162 
between the 2nd and 3rd years; P = 0.166 between the 3rd and 
4th years; P = 0.67 between the 4th and 5th years; P = 0.88 
between the 5th and 6th years; and P = 0.694 between the 6th 
and 7th years).
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295 subjects with initial PSA levels < 10 ng mL-1, 33% 
showed changes of more than ± 1.0 ng mL-1 in 90 days. 
Similarly, Riehmann et al. [20] reported a biological 
fluctuation of 55% in 39 subjects without prostate can-
cer in whom PSA was measured more than three times, 
with an average measurement interval of 10.3 months. 
It is necessary to optimize the calculation method, 
measurement interval and cutoff values to distinguish 
the PSAV rise due to prostate cancer from that due to 
physiological fluctuation.  
For the most part, the reported studies consider 
PSAV with regard to the diagnosis of prostate cancer as 
follows: a rapid improvement before the cancer diagno-
sis can suggest the aggressiveness of the pathology, as 
stated by D’Amico and co-workers [13, 14].
Considering the importance of PSAV and its clinical 
application in the field of prostate cancer, it is also nec-
essary to measure PSA kinetics in a large healthy popu-
lation.  For this purpose, we entered the Central Labo-
ratory of the Hospital–University of Modena, searching 
for a specific population aged > 75 years and with PSA 
value < 2.0 ng mL-1.  In those who meet these criteria, 
the risk of prostate cancer is very low; although a valid 
PSA threshold does not exist, Ito et al. [21] described 
an age-specific reference range of PSA that can in-
crease the sensitivity, specificity and efficiency of PSA 
to 92.4%, 91.2% and 84.3%, respectively.  According 
to their finding, the cutoff value for patients aged > 75 
years was set at 4.0 ng mL-1.  
Similarly, if the recommended threshold for prostate 
biopsies in young men is set at 2.0 ng mL-1, the prostate 
cancer risk in our cohort of patients is very low.  
A minimum of 0.2 ng mL-1 was chosen in our study 
to exclude patients undergoing therapies that could 
lower the PSA value.  For each patient, a retrospec-
tive history of all PSA values for the last 10 years was 
recorded to create a database enrolling subjects with at 
least five PSA assessments for at least 5 years.  
The main bias of our retrospective research, as oc-
curs in many other studies on screening populations, is 
that the risk of prostate cancer is consistent at any PSA 
value or range: failure to reach a certain cutoff cannot 
assure us about the absence of the neoplasm.  We tried 
to minimize this risk by selecting an elderly population 
with PSA set < 2.0 ng mL-1, which is a value in accor-
dance with most recent suggestions about age-related 
PSA values.  Another bias is the lack of clinical infor-
mation: we tried to reduce this inaccuracy by excluding 
patients with two or more PSA assessments per year, 
thus avoiding the risk of clinical prostatis, diagnosis or 
recurrence of prostate cancer.
Beyond these biases, we think that the volume of 
the cohort in this large-scale study must be highlighted, 
with a total of 1 327 PSA values followed retrospec-
tively for a minimum of 5 years, and thus representing 
the main impact and power of the research.  In addition, 
the recent publication of similar studies [22] shows that 
this is a very current and relevant theme in the diagno-
sis of prostate cancer.
Our outcomes strengthen the point of view of 
Scales et al. [23], who analyzed the benefit of PSA test-
ing in men older than 75 years and concluded that up to 
a third of those patients have an average life expectancy 
of  < 10 years.  
As suggested in the recent ‘prostate, lung, colorec-
tal and ovarian cancer screening trial’ [24], screen-
ing steps can be optimized.  The authors of that study 
concluded that screening every 5 years for baseline 
PSA < 1 ng mL-1 and every 2 years for PSA 1–2 ng mL-1 
could result in a 50% reduction in PSA tests and in < 1.5% 
of men missing earlier positive screens.  Our outcomes 
confirm that yearly repeated PSA assessment in an el-
derly population, with a potential life expectancy of < 10 
years and with normal PSA values at baseline, may have 
low significance in urological practice and screening pro-
grams.
However, although repeated PSA assessments 
lose significance in older population, a recent study 
by Ulmert et al. [25] showed the importance of PSA 
before the age of 50 years, invoking this marker as a 
predictor of prostate cancer up to 25 years later.  This 
outcome confirms the need for a risk-stratified screen-
ing approach for clinically significant diseases.  
Even though the popularity of PSA is widely de-
bated owing to its lack of sensitivity and specificity and 
the absence of an agreed-upon threshold, it still remains 
the most powerful marker in the management of pros-
tate cancer diagnosis.  PSAV has gained popularity for 
improving the usefulness of this indicator, and several 
studies have focused on the variation characterizing 
cancerous degeneration.  Longitudinal assessment of 
PSA in an elderly and supposedly healthy population 
may help define its physiological kinetics.  Our study 
represents a long-term retrospective PSA observation 
in a population aged > 75 years: PSA variation from 
the first to the last and from the highest to the low-
est values seems to be insignificant.  Even if followed 
up year by year, PSA fluctuations seem insignificant. 
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These outcomes help to define the possible phases of a 
screening program, especially if the program is targeted 
at elderly patients with a life expectancy lower than 10 
years, with a low risk for prostate cancer.  Physicians 
and urologists should consider these findings and apply 
them in their urological practice.
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